It seems to be the thought from many good posters on the other board that B is far enough along for a partnership of some sort now and that P will reach that status as soon as the top line comes out in the next handful of weeks.

I have always thought that P might be on the block for partnering after top line results are given should they be as good as many believe they will be.

I cannot accept that B would be on the block at this stage because its value goes up so exponentially with more trials run by IPIX.

The most startling divergence in thought, though, is that I hear many saying that K should be partnered now so that the appropriate funds and effort can be given it which IPIX cannot provide currentlywhile other very good posters propose that K will never be partnered out until much more is known of its value and breadth of effectiveness across the cancer spectrum.

Somebody compared us to a game of 3 card monty and my thought was that if that is the case there must be a ball under every card as we win with whatever route we choose to take.

I find it exciting waiting for the shoe to drop on which route IPIX is to take, knowing that we have the right personnel making the decision for us.